NUMBERS

In oncology even more than in other medical disciplines, the therapeutic results reported in the literature are interpreted in statistical terms. Bearing in mind that our patients are not "numbers", each veterinarian who should discuss the treatment plan for a cancer patient has to provide numerical values on the expectations of care and survival. Here are some data drawn from the current literature that can serve as a handbook, not before you have defined the objectives that every cancer therapy must set itself, that is: first - to improve the quality of life; second - if possible, to cure; third - if possible, to heal permanently. In the light of these three principles, we invite critical reading of simple numeric data declining it according to the situation of each patient. The data presented above can obviously be subject to change based on the refining of therapeutic aids. 

Oral

  • EPULIS: shorter time to progression based on the parameter T; appropriate therapy with more than 40 Gy. Median time disease-free: 3000 days.
  • ORAL SQUAMOUS CELL CARCINOMA (DOG): 45 Gy in 9 fx to 5 Gy; effective control tumor to 1 year in 75%, 3 years in 55% of cases. If it is in the back seat with the worst prognosis for proximity lymphatics.
  • ORAL FIBROSARCOMA: Effective control of the disease progression to 1 year in 70%; 3 years in 40%. Cytoreductive surgery followed by RT: median survival 540 days.
  • ORAL SQUAMOUS CELL CARCINOMA (CAT):

a) emimandibolectomia, linfadenectomia and radiation therapy guarantee a median survival of 420 days;

b) better IMRT and radiosurgery.

  • ORAL MELANOMA: 48 Gy in fx to 4 Gy Mon-Wed-Sat.

        T1: median survival 38 months.

          T2 -T3: median survival 12 months.

          Or: 36 Gy in 6 fx to 6 Gy weekly + carboplatin 90 mg/m2 1 hour before irradiation.

          25% of local relapse.

          Metastasis development: 1 year.

Nasal

  • 42 Gy in 10 fx dayly, CT 6 weeks after, with subsequent surgical resection in case of neoplastic residual. Median survival time: 47 months.
  • LINFOPROLIFERATIVES IN CATS: stable and durable risponse to radiation therapy  24 Gy: 3 Gy in 8 sessions Lu- Mer-Sab.

Encephalic

  • Median survival 2 years. 

       Effective control of the disease to 1 year in 70% of cases; 2 years in 50% of cases.

  • PITUITARY TUMORS: excellent mass control, endocrinopathy is much better controlled in cats, less in dogs. 

Sarcomas in extremities and trunk

  • 5-year survival of 80% for post/surgical cytoreductive RT. Median survival 2500 days.

          Radiotherapy as the only aid in vicinity of digital pads with excellent and durable response. 

Mastocytoma

  • For mastocytoma G2, cytoreductive surgery and RT determine effective control 2 years in 90% of cases, also with margins involved.
  • Stages II and III: cytoreduction + prime focused RT and lymph nodes involved: disease/free time 3 years. 

Thyroids

  • Infiltrative tumors: 48 Gy in fx of 4 Gy.

        Survival 80% of cases during 3 years. 

Thymoma

  • In case of RT as the only therapeutic aid: median survival of 2 years in cats. 

Perianal

  • RT combined with chemotherapy and surgery: median survival of 2 years. 

Lymphoma

  • The local-regional RT associated to chemotherapy only at stages I and II. In generalized lymphoma, induced the remission, can be provided 2 cycles of 8 Gy at 1 month, obtaining a median survival of 2 years.
Go to top